A two-gene methylation signature for the diagnosis of bladder cancer in urine

Epigenomics. 2019 Feb;11(3):337-347. doi: 10.2217/epi-2018-0094. Epub 2019 Feb 1.

Abstract

Aim: To analyze the potential of 14 cancer-associated genes, including six miRNAs, for bladder cancer (BC) diagnosis in urine.

Patients & methods: DNA methylation levels of 14 genes were analyzed in urine of 72 BC patients and 75 healthy controls using quantitative methylation-specific PCR. Multivariate logistic regression analysis was used to determine an optimal marker panel.

Results: Ten genes were significantly hypermethylated in BC patients. The GHSR/MAL combination showed the best diagnostic performance, reaching a sensitivity of 92% (95% CI: 86-99) and a specificity of 85% (95% CI: 76-94).

Conclusion: We identified a novel two-gene panel with a high diagnostic accuracy for BC that can be applied in a noninvasive, urine-based test.

Keywords: biomarkers; methylation; molecular diagnostics; urinary bladder neoplasms; urine analysis.

MeSH terms

  • Aged
  • Biomarkers, Tumor*
  • Cell-Free Nucleic Acids* / urine
  • DNA Methylation*
  • Female
  • Humans
  • Male
  • Molecular Diagnostic Techniques
  • Neoplasm Grading
  • Neoplasm Staging
  • Polymerase Chain Reaction
  • ROC Curve
  • Sensitivity and Specificity
  • Urinary Bladder Neoplasms / diagnosis*
  • Urinary Bladder Neoplasms / genetics*
  • Urinary Bladder Neoplasms / urine

Substances

  • Biomarkers, Tumor
  • Cell-Free Nucleic Acids